EA201791735A1 - Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения - Google Patents

Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения

Info

Publication number
EA201791735A1
EA201791735A1 EA201791735A EA201791735A EA201791735A1 EA 201791735 A1 EA201791735 A1 EA 201791735A1 EA 201791735 A EA201791735 A EA 201791735A EA 201791735 A EA201791735 A EA 201791735A EA 201791735 A1 EA201791735 A1 EA 201791735A1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza
virus
binding molecules
ways
application
Prior art date
Application number
EA201791735A
Other languages
English (en)
Other versions
EA038407B1 (ru
Inventor
Буррис Бранденбург
Роналд Вогелс
Йост А. Колкман
Роберт Хайнц Эдвард Фризен
Original Assignee
Янссен Вэксинс Энд Превеншн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Вэксинс Энд Превеншн Б.В. filed Critical Янссен Вэксинс Энд Превеншн Б.В.
Publication of EA201791735A1 publication Critical patent/EA201791735A1/ru
Publication of EA038407B1 publication Critical patent/EA038407B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к мономерным и мультимерным связывающим молекулам, способным специфично связываться с гемагглютинином (НА) по меньшей мере двух штаммов вируса гриппа А, при этом указанные штаммы содержат НА двух различных подтипов НА из филогенетической группы 2; или способное специфично связываться с гемагглютинином (НА) по меньшей мере одного вируса гриппа А из филогенетической группы 1 и по меньшей мере одного штамма вируса гриппа А из филогенетической группы 2; или способное специфично связываться с гемагглютинином (НА) по меньшей мере одного штамма вируса гриппа В. Связывающие молекулы предпочтительно также способны нейтрализовать по меньшей мере два штамма вируса гриппа А из филогенетической группы 2; или способны нейтрализовать по меньшей мере один штамм вируса гриппа А из филогенетической группы 1 и по меньшей мере один штамм вируса гриппа А из филогенетической группы 2; или способны специфично нейтрализовать по меньшей мере один штамм вируса гриппа В.
EA201791735A 2015-02-05 2016-02-05 Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения EA038407B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153957 2015-02-05
PCT/EP2016/052556 WO2016124768A1 (en) 2015-02-05 2016-02-05 Binding molecules directed against influenza hemagglutinin and uses thereof

Publications (2)

Publication Number Publication Date
EA201791735A1 true EA201791735A1 (ru) 2017-11-30
EA038407B1 EA038407B1 (ru) 2021-08-24

Family

ID=52484335

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791735A EA038407B1 (ru) 2015-02-05 2016-02-05 Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения

Country Status (17)

Country Link
US (3) US10370435B2 (ru)
EP (1) EP3253411A1 (ru)
JP (2) JP6772157B2 (ru)
KR (1) KR20170107562A (ru)
CN (1) CN107207611B (ru)
AU (1) AU2016214304B2 (ru)
BR (1) BR112017016417A2 (ru)
CA (1) CA2975655C (ru)
EA (1) EA038407B1 (ru)
HK (1) HK1243925A1 (ru)
IL (1) IL253653B (ru)
MX (1) MX2017010009A (ru)
MY (1) MY186585A (ru)
PH (1) PH12017501216A1 (ru)
SG (2) SG11201705614QA (ru)
WO (1) WO2016124768A1 (ru)
ZA (1) ZA201705300B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SG11201705614QA (en) 2015-02-05 2017-08-30 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
KR20190071714A (ko) * 2016-10-27 2019-06-24 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 중화 화합물
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
AU2018229293A1 (en) 2017-02-28 2019-08-29 Janssen Biotech, Inc. Influenza vaccines based on AAV vectors
LT3589730T (lt) 2017-02-28 2024-03-12 The Trustees Of The University Of Pennsylvania Adenoasocijuoto viruso (aav) monofiletinės grupės f vektorius, ir jo panaudojimo būdai
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
PT3694529T (pt) 2017-10-13 2024-09-20 Harpoon Therapeutics Inc Proteínas triespecíficas e métodos de utilização
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． Ｂ細胞成熟抗原結合タンパク質
JP7162190B2 (ja) * 2018-07-17 2022-10-28 パナソニックＩｐマネジメント株式会社 インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法
US20220017626A1 (en) * 2018-09-21 2022-01-20 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
JP2023551666A (ja) * 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド Ａ型インフルエンザウイルスに対する抗体
JP2024512741A (ja) * 2021-03-31 2024-03-19 キソジ・バイオテクノロジー・インコーポレイテッド 腫瘍及び／又は免疫細胞を標的化する結合剤
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
WO2024163545A1 (en) * 2023-02-01 2024-08-08 Anwita Biosciences, Inc. Anti-pd-1/il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
CN117924470B (zh) * 2023-12-14 2024-09-20 南京大学 一种靶向甲型流感病毒核蛋白纳米抗体的制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
PT1161548E (pt) 1999-04-15 2005-06-30 Crucell Holland Bv Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus
GB0522460D0 (en) 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
CN102046656A (zh) 2008-03-28 2011-05-04 航道生物技术有限责任公司 针对病毒抗原的中和性分子
AU2009254501B2 (en) * 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010037046A1 (en) * 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8563305B2 (en) 2009-04-30 2013-10-22 Oklahoma Medical Research Foundation Rapid generation of antibodies
CN102276719B (zh) * 2010-06-09 2014-12-24 中国科学院生物物理研究所 禽流感病毒单域抗体、五聚抗体及其制备和应用
CN102023212B (zh) 2010-09-28 2014-04-02 汕头大学医学院 一种流感病毒神经氨酸酶抗体的快速检测方法
BR112014000263B1 (pt) * 2011-07-14 2022-01-18 Janssen Vaccines & Prevention B.V. Anticorpo isolado capaz de se ligar especificamente à proteína hemaglutinina (ha) dos subtipos de vírus influenza b, e, composição farmacêutica que o compreende
HUE044089T2 (hu) * 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
NZ628382A (en) 2012-03-08 2017-03-31 Janssen Vaccines & Prevention Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP3492101A3 (en) 2012-05-10 2019-10-23 Massachusetts Institute Of Technology Agents for influenza neutralization
CN104098692B (zh) * 2013-04-02 2018-11-30 厦门大学 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
SG11201705614QA (en) * 2015-02-05 2017-08-30 Janssen Vaccines & Prevention Bv Binding molecules directed against influenza hemagglutinin and uses thereof

Also Published As

Publication number Publication date
CA2975655A1 (en) 2016-08-11
EA038407B1 (ru) 2021-08-24
BR112017016417A2 (pt) 2018-03-27
HK1243925A1 (zh) 2018-07-27
JP6772157B2 (ja) 2020-10-21
MX2017010009A (es) 2017-10-24
US20200299364A1 (en) 2020-09-24
US11136379B2 (en) 2021-10-05
IL253653A0 (en) 2017-09-28
KR20170107562A (ko) 2017-09-25
CA2975655C (en) 2023-09-19
US10370435B2 (en) 2019-08-06
JP2020171288A (ja) 2020-10-22
ZA201705300B (en) 2021-05-26
IL253653B (en) 2021-10-31
EP3253411A1 (en) 2017-12-13
JP2018505677A (ja) 2018-03-01
CN107207611B (zh) 2021-11-09
AU2016214304B2 (en) 2021-11-11
US10703804B2 (en) 2020-07-07
AU2016214304A1 (en) 2017-07-20
CN107207611A (zh) 2017-09-26
SG10202103618XA (en) 2021-05-28
US20190359693A1 (en) 2019-11-28
MY186585A (en) 2021-07-28
PH12017501216A1 (en) 2018-01-15
WO2016124768A1 (en) 2016-08-11
SG11201705614QA (en) 2017-08-30
US20180016323A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
EA201791735A1 (ru) Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
EA201990033A1 (ru) Вариантные аденоассоциированные вирусы и способы их применения
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
DK3400290T5 (da) Onkolytisk virusstamme
TR201901582T4 (tr) Kapsid
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201890999A1 (ru) Вакцина против вируса простого герпеса
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CR20110084A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
EA201692535A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201791086A1 (ru) Человеческие антитела против гемагглютинина вируса гриппа
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201500854A1 (ru) Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а
EA201491656A1 (ru) Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения
EA201690372A1 (ru) Азапиридоновые соединения и их применение
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EA201890322A1 (ru) Новый вид тобамовируса
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
BR112017021613A2 (pt) promotores induzíveis de trichoderma reesei